FKBP5, a glucocorticoid receptor that can bind to immunosuppressive agents such as tacrolimus (FK506) and cyclosporin A, has emerged as a promising therapeutic target in the fields of cancer, psychiatric disorders, and metabolic diseases26,27. Here, FKBP5 is linked to psychiatric disorder.